zurig怎么吃？

(Febuxostat) is a new non-purine selective xanthine oxidase inhibitor. In my country, zurig (Febuxostat) is a first-line drug that inhibits uric acid production. At the same time, zurig (Febuxostat) is also suitable for the long-term treatment of hyperuricemia in patients with gout. How to eat zurig?

The starting dose of zurig (febuxostat) is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh classes A and B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh class C) should use zurig (febuxostat) with caution.

Pediatric Use: The safety and effectiveness of this product in treating patients under 18 years of age have not been established.

Elderly patients: No dosage adjustment is required for elderly patients. According to foreign literature reports, in zurig clinical studies, people aged 65 and over accounted for 16% of the total number of subjects, and people aged 75 and over accounted for 4%. Comparing subjects of different age groups, there is no clinically significant difference in effectiveness and safety, but it cannot be ruled out that some elderly patients are more sensitive to this product. After multiple oral administrations of zurig to elderly subjects (65 years and above), Cmax and AUC24 were similar to those of young subjects (18 to 40 years old).

Use in pregnant and lactating women: Pregnant women FDA pregnancy safety classification is Category C: Inadequate controlled studies have been conducted in pregnant women. Therefore, zurig should only be used during pregnancy if it is confirmed that the potential benefits outweigh the risks to the fetus. Zurig did not show teratogenicity during organogenesis when administered orally to rats and rabbits at 48 mg/kg (equivalent to 40 and 51 times the plasma exposure at the human dose of 80 mg/d, respectively, based on body surface area conversion). However, during the organogenesis and lactation periods, oral doses of up to 48 mg/kg in rats (equivalent to 40 times the plasma exposure at the human dose of 80 mg/d based on body surface area conversion) can lead to increased mortality and reduced weight gain in neonatal rats. A study on rats by lactating women found that zurig was excreted in breast milk. However, it is not known whether zurig is excreted in human milk. Since many drugs can be secreted into breast milk, lactating women should use this product with caution.

Overdose: Studies in healthy subjects showed no dose-limiting toxicities when administered at 300 mg/day for 7 days. There have been no reports of overdose of this product in clinical studies. If the patient overdoses on this product, he or she should receive symptomatic treatment and supportive therapy.